Windward Bio Group AG

Windward Bio Group AG

NNASDAQ:WWB
24.29
USD
+0.28
(+1.15%)
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Semi-annual Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Semi-annual Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Semi-annual Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

CEO
Luca Santarelli
Full Time Employees
33
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Aeschenplatz 6 Basel BS Switzerland 4052
IPO Date
Nov 13, 2026
Business
Windward Bio Group AG is clinical-stage biotechnology company, which developing long acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. It focuses on discovery, development, and manufacture of drug products for the treatment of immunological conditions. The company was founded by Luca Santarelli on July 05, 2024 and is headquartered in Basel, Switzerland.